ClinicalTrials.gg
RecruitingNCT07484724Updated Apr 22, 2026

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

A Phase 2 interventional study of JS212 and JS001 in Advanced Esophageal Squamous Cell Carcinoma, sponsored by Shanghai Junshi Bioscience Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by Shanghai Junshi Bioscience Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
280
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma — 10 open to participants now, 11 under way, 4 of them phase 3. toripalimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
3rd of 18
280 · median 69
Started
2026
with 3 others
Phase 2
13 of 18
6 open now
Primary completion
2027-06
later than 3 of 10 live
Registered
16th of 18
by date
Lead sponsor
2 of 18
Shanghai Junshi Bioscience Co., Ltd.

Among the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, this one is the 3rd largest by planned enrollment, is one of 4 that started in 2026, is one of 13 in phase 2, reaches primary completion later than 3 of the 10 other live ones, and was the 16th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

10 of the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).

03

Conditions studied

  • Advanced Esophageal Squamous Cell Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 75 years (inclusive) at the time of signing the Form (ICF).
  2. or cytologically confirmed esophageal squamous cell carcinoma (ESCC) that is locally advanced, recurrent, or , and not amenable to radical treatment.
  3. No prior systemic anti-tumor therapy. For patients who received /adjuvant therapy or radical concurrent chemoradiotherapy, the interval from the last dose of chemotherapy to disease recurrence or progression must be > 6 months to be eligible for screening.
  4. At least one per (RECIST 1.1).
  5. (ECOG) performance status of 0 or 1.
  6. Expected survival ≥ 12 weeks

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with any of the following: or anti-PD-L1 antibody therapy; ADC therapy targeting EGFR and/or HER3, or ADC therapy with a topoisomerase I inhibitor as the toxic payload;
  2. Subjects at high risk of bleeding or esophageal fistula, e.g., lesions with large ulcers or direct invasion of vital adjacent organs such as the aorta or trachea;
  3. Subjects with a history of gastrointestinal perforation and/or fistula within 6 months prior to the first dose;
  4. Presence of active central nervous system (CNS) ;
  5. Active disease requiring systemic therapy (e.g., or agents) within 2 years prior to the first dose;
  6. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 per v6.0 or to the level specified in the inclusion/exclusion criteria;
  7. Severe cardiovascular or cerebrovascular disease;
  8. Known or severe allergic reaction to the study treatment drugs, any of their components, or their ;
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Cohort 1:JS212+JS001

    Drug: JS212 · Drug: JS001

  • Experimental
    Cohort 2:JS212+JS001+5-FU

    Drug: JS212 · Drug: JS001 · Drug: 5-FU

Interventions

06

What researchers measure

Primary outcomes

  1. dose-limiting toxicity (DLT)

    Abnormal changes in laboratory and other tests with clinical significance

    Time frame: up to 4 years

  2. adverse event(AE)

    Abnormal changes in laboratory and other tests with clinical significance

    Time frame: up to 4 years

  3. RP3D

    Recommended dose for phase III trial

    Time frame: up to 4 years

  4. Objective response rate (ORR) based on Response Evaluation Criteria In Solid Tumors 1.1 (RECIST1.1)

    Defined as the proportion of subjects who achieved partial response (PR) or complete response (CR)

    Time frame: up to 4 years

Secondary outcomes

  1. Progression free survival(PFS)

    The time from first dose to Disease progression or death

    Time frame: up to 2years

  2. overall survival (OS)

    The time from first dose to death from any cause

    Time frame: up to 4 years

  3. immunogenicity

    Incidence of Anti-Drug Antibody (ADA)

    Time frame: up to 2years

Other outcomes

  1. Biomarker

    exploratory analysis of the correlation between potential biomarkers (which may include PD-L1, EGFR, HER3, etc.) and clinical efficacy of JS212 combination therapy.

    Time frame: up to 2years

07

Study locations

1 of 1 sites recruiting
  • Cancer Hospital of Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality 100142, China
    Recruiting
    • Jing Huang, Ph.D · Contacthuangjingwg@163.com · 010-87788102
    • Jing Huang, Ph.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 153 non-industry phase 2 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 55. This study's planned 14 months is below that.

Counting every sponsor, half of 174 studies reached it within 41 months; a quarter within 28 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2026
First posted
Mar 20, 2026
StartActual
Apr 13, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Apr 1, 2028
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07484724
Responsible party
Sponsor
First posted
Mar 20, 2026
Start date
Apr 13, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Apr 22, 2026

Study contacts

Chengbo Jia
Contact
chengbo_jia@junpharma.com
+8618547265054

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: JS212 · Toripalimab

Start the discussion